To the Editor: Takahashi et al. 1 have recently described the effect of nicotinamide for controlling hyperphosphatemia in dialysis patients. However, Rottembourg et al. 2 reported thrombocytopenia in the same setting. We have started a prospective, open-label trial to study the efficiency and safety of nicotinamide in our hemodialysis patients with resistant hyperphosphatemia. Unlike Takahashi,...
